Table 1 The synergistic antitumor effect of KPT-330 combined with bortezomib or gemcitabine in TCL and MCL cell lines. Synergy was defined as a combination index<1

From: The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells

  

Gemcitabine (ηM)

 

Bortezomib (ηM)

  

1

10

20

50

 

2

5

10

TCL

KPT 0.1 µM (CI)

3.2

1.5

0.67

0.96

KPT 0.1 µM (CI)

1.37

0.88

0.54

 

KPT 0.25 µM (CI)

1.82

1.8

0.87

0.78

KPT 0.25 µM (CI)

1.11

0.84

0.46

 

KPT 0.5 µM (CI)

0.88

1.33

0.60

0.55

KPT 0.5 µM (CI)

0.65

0.40

0.25

MCL

KPT 0.1 µM (CI)

2.36

0.59

0.69

1.06

KPT 0.1 µM (CI)

0.71

0.61

0.39

 

KPT 0.25 µM (CI)

1.97

0.66

0.65

1.01

KPT 0.25 µM (CI)

1.41

1.04

0.48

 

KPT 0.5 µM (CI)

0.70

0.61

0.65

0.94

KPT 0.5 µM (CI)

0.75

0.63

0.14

  1. TCL T-cell lymphoma (representative cell line: SR-786), MCL mantle cell lymphoma (representative cell line: JVM-2), CI combination index, KPT KPT-330
Back to article page